Tolerizing Liposomes for Antigen-Specific Immunotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for allergy, asthma, and autoimmune diseases such as type I diabetes, rheumatoid arthritis, and multiple sclerosis using antigen-specific Tregs or tolerogenic dendritic cells face challenges including unpredictable function persistence, risks of trans-differentiation, pan-immunosuppression, and logistical and cost issues with autologous cell therapy, as well as limitations with liposomal targeting techniques.
Innovation Solution
A pharmaceutical composition of tolerogenic liposomes tailored for effective phagocytosis, loaded with maturation inhibitors like calcipotriol or glucocorticoids, and antigens or allergens, embedded in a PLGA-PEG-PLGA triblock copolymer matrix for sustained local delivery, which mimics apoptotic cells to induce antigen-specific tolerance and suppress immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adoptive transfer of antigen-specific Tregs is used, then immunological tolerance can be restored, but the function persistence is unpredictable and trans-differentiation risks occur
Solution Approach 1:
The patent uses liposomes as artificial copies of apoptotic cells, presenting antigens in a controlled manner that mimics natural tolerance induction without the unpredictability of live cell transfer. These liposomal structures provide consistent, reproducible antigen presentation that avoids trans-differentiation risks while maintaining reliability.
Solution Approach 2:
The patent introduces liposomes as intermediary carriers between the antigen and the immune system. These liposomes mediate antigen presentation to dendritic cells and T cells, providing a controlled interface that ensures consistent immunological responses without the variability and safety risks associated with direct Treg cell transfer.
2Adaptability or versatility
If pan-immunosuppression is achieved, then broad immune responses are suppressed, but antigen-specific tolerance is reduced
Solution Approach 1:
The patent applies local quality by presenting different antigens to different subsets of dendritic cells and T cells within the same system. Each liposome population maintains antigen-specific activity while collectively achieving broad coverage, ensuring that suppression is targeted rather than pan-immunosuppressive.
3Adaptability or versatility
If autologous cell therapy is used, then personalized treatment is achieved, but logistical complexity and costs increase
Solution Approach 1:
The patent replaces complex autologous cell therapy with simplified liposomal copies that can be manufactured centrally and administered readily. These liposomal products capture the essential antigen-specific tolerance induction function without requiring complex cell collection, expansion, and quality control processes.
4Manufacturing precision
If liposomal targeting techniques are used, then antigen delivery is improved, but delivery efficiency and sustained release are limited
Solution Approach 1:
The patent employs nested structures where liposomes are embedded within a biodegradable polymer matrix. This nested arrangement allows sustained release of liposomes over time, improving delivery efficiency and duration while maintaining the precision of targeted antigen delivery to immune cells.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition achieves sustained local delivery of tolerizing agents, reducing the risk of global tolerance and adverse effects, while enhancing suppressive activity of Tregs and inhibiting effector T cell responses, thereby providing a broadly applicable method for restoring lasting immunological tolerance.
Implementation Method 1
embedded in a PLGA-PEG-PLGA triblock copolymer matrix for sustained local delivery
Implementation Method 2
tolerogenic liposomes tailored for effective phagocytosis
Data Source
AI summary
The invention relates to a pharmaceutical composition for the treatment of allergic and autoimmune diseases by in vivo generation of tolerogenic dendritic cells (DCs) and macrophages using tolerizing liposomes loaded with at least one maturation inhibitor of DCs and at least one antigen or allergen or peptide derived thereof, made of at least one preparation, and comprising a matrix suitable for locally restricted sustained release of therapeutically effective doses of therapeutics including tolerogenic liposomestailored for effective phagocytosis, at least one immune modulator of phagocytosis, and optionally at least one immune modulator suitable for enhancing the suppressive function of regulatory T cells and/or inhibiting the production of pro-inflammatory cytokines,and/or inhibiting the biological activity of secreted pro-inflammatory cytokinesat the site of antigen or allergen presentation.